Catalonian Cancer Strategy, Department of Health, Barcelona, Spain.
Biomedical Research Institute of Bellvitge (IDIBELL), University of Barcelona (UB), Barcelona, Spain.
Eur J Public Health. 2022 Nov 29;32(6):852-857. doi: 10.1093/eurpub/ckac166.
As a system of European Reference Networks (ERNs) emerges, the differences in quality of care for patients with rare cancers may increase at national level. We aimed to elucidate the processes and healthcare planning principles through which the reference centres (RCs) for rare cancers are embedded in national health systems.
We used a multiple case-study design based on the experiences of Czechia, Finland, France, Italy, Lithuania and Spain. Using sarcoma as an example of rare cancer, 52 semi-structured interviews were conducted during on-site visits, including a multidisciplinary group of professionals, Ministry of Health professionals, patient representatives and European policymakers.
The comparative analysis showed substantial heterogeneity in the processes for formalizing RCs' status and in their levels of integration in the different health systems, but two models (centre-based and the network-based) can be envisaged at national level. RCs for rare cancers were legally established only in France and Spain. Expert clinicians cooperate in a structured way, using network mechanisms, in France and Italy, and these countries, plus Finland and Lithuania, had a referral system to facilitate patients' access from non-expert centres to RCs. Seven key healthcare planning principles in instituting RCs at the national level were identified.
The conditions governing patient access to treatment centres-whether RCs or not-are decided at the national level. It is advisable to progressively align the European and national levels so that the RCs that participate in the ERNs also play a significant role at the national level.
随着欧洲参考网络(ERNs)系统的出现,患者接受罕见癌症治疗的质量可能在国家层面上存在差异。我们旨在阐明参考中心(RCs)嵌入国家卫生系统的过程和医疗保健规划原则。
我们采用基于捷克、芬兰、法国、意大利、立陶宛和西班牙经验的多案例研究设计。以肉瘤为例,在现场访问期间进行了 52 次半结构化访谈,包括多学科专业人员、卫生部专业人员、患者代表和欧洲政策制定者。
比较分析显示,RCs 地位正式化的过程以及它们在不同卫生系统中的整合程度存在很大差异,但可以在国家层面上设想两种模式(以中心为基础和基于网络的模式)。只有法国和西班牙在法律上设立了罕见癌症 RC。法国和意大利的专家临床医生以结构化的方式合作,使用网络机制,这两个国家以及芬兰和立陶宛都有一个转诊系统,以方便非专家中心的患者转诊至 RC。在国家层面建立 RC 时确定了七个关键的医疗保健规划原则。
决定患者是否能够进入治疗中心(无论是 RC 还是其他中心)的条件是在国家层面上决定的。建议逐步协调欧洲和国家层面,使参与 ERNs 的 RC 也在国家层面发挥重要作用。